Analyst: Lundbeck could reach 2020 targets, but…
Lundbeck CEO Ulf Wiinberg wants to at least double the company’s top line by 2020, and he says that it could even triple. The latter notion is definitely out of the question from the point of view of the stock market, says an industry analyst.
by Benjamin Werner Christensen
“Our ambition is to have Cipralex fully replaced by Brintellix 2020, to have doubled our sales on international markets by 2020, and finally it’s our ambition that we double Lundbeck’s overall sales from the current level. We have a sales potential that could make Lundbeck two to three times bigger than the company we know now. We believe we have what it takes to continue the long term growth in Lundbeck.”
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Lundbeck eyes solid premium in Genmab field
For abonnenter
Bleak years ahead for Lundbeck
For abonnenter
Lundbeck: This is our focus for 2014 and 2015
For abonnenter
